KEYNOTE-086 cohort B: pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC).
Authors
Adams, SLoi, S
Toppmeyer, D
Cescon, D
De Laurentiis, M
Nanda, R
Winer, E
Mukai, H
Tamura, K
Armstrong, Anne C
Liu, M
Iwata, H
Ryvo, L
Wimberger, P
Rugo, H
Tan, A
D'Aquanno, C
Ding, Y
Karantza, V
Schmid, P
Affiliation
Perlmutter Cancer Center at NYU Langone Medical Center, New York, NYIssue Date
2018-02-14
Metadata
Show full item recordCitation
KEYNOTE-086 cohort B: pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC). 2018, 78(4 Suppl): PD6-10 Cancer ResJournal
Cancer ResearchDOI
10.1158/1538-7445.SABCS17-PD6-10Type
ArticleMeetings and Proceedings
Language
enISSN
0008-54721538-7445
ae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.SABCS17-PD6-10